Acadia’s Nuplazid Needs Another Study For Alzheimer’s Psychosis, US FDA Panel Says

 
• By Sue Sutter
  
Truck blocking road
For Nuplazid to add an indication in Alzheimer's psychosis, there is no way around conducting another study, an FDA panel member said. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers